 |
(Photo= Yonhap news) |
[Alpha Biz= Reporter Kim Sangjin] Samsung Biologics has announced a contract for pharmaceutical contract manufacturing (CMO) worth approximately 211.5 billion Korean Won with Kiniksa Pharmaceuticals, a US-based company.
On the 25th, Samsung Biologics disclosed that it has entered into a CMO agreement with Kiniksa Pharmaceuticals valued at 211.5 billion Korean Won.
The contract period for this agreement is from June 21, 2022, to December 31, 2031.
In May last year, Samsung Biologics signed a letter of intent for biopharmaceutical CMO services with another pharmaceutical company.
This contract represents the execution of that letter of intent from last year and amounts to approximately 5.72% of Samsung Biologics' total revenue of 3.6945 trillion Korean Won reported last year.
AlphaBIZ Kim SangJin(letyou@alphabiz.co.kr)
